The new alliance with FSI

Sterling and FSI announce the signing of a partnership agreement with the aim of accelerating the company's development.

With sales of about €50 million and more than 300 employees, Sterling is a leading manufacturer of active ingredients used to treat diseases in oncology, respiratory and dermatology. More than 90 percent of its turnover is generated outside its home country. Over the years Sterling has managed to establish itself as a long-term partner of the world's leading pharmaceutical companies, becoming a benchmark in terms of innovation and production efficiency, quality, and reliability.    Italy is the leading pharmaceutical manufacturing country in Europe with a turnover of €31 billion, followed by Germany and France. Italy is also the European leader in terms of exports, accounting for about 85 percent of total turnover and growing by 140 percent in the decade 2010-2020. Despite the aggregate leadership at the European level, only 11 companies have a turnover above €500 mln, that’s why the Italian pharmaceutical industry is characterized by a high level of fragmentation.  The pharmaceutical sector is one of the priority sectors for FSI, consistent with FSI's vocation as a "mission-related" investor in the Italian economy and with the National Recovery and Resilience Plan. 

With sales of about €50 million and more than 300 employees, Sterling is a leading manufacturer of active ingredients used to treat diseases in oncology, respiratory and dermatology. More than 90 percent of its turnover is generated outside its home country. Over the years Sterling has managed to establish itself as a long-term partner of the world's leading pharmaceutical companies, becoming a benchmark in terms of innovation and production efficiency, quality, and reliability.    Italy is the leading pharmaceutical manufacturing country in Europe with a turnover of €31 billion, followed by Germany and France. Italy is also the European leader in terms of exports, accounting for about 85 percent of total turnover and growing by 140 percent in the decade 2010-2020. Despite the aggregate leadership at the European level, only 11 companies have a turnover above €500 mln, that’s why the Italian pharmaceutical industry is characterized by a high level of fragmentation.  The pharmaceutical sector is one of the priority sectors for FSI, consistent with FSI's vocation as a "mission-related" investor in the Italian economy and with the National Recovery and Resilience Plan. 

"The objective is to participate with determination in a necessary evolution of a sector of great pride for our country. The new alliance with FSI is designed to equip Sterling with an important financial asset, which will enable it to acquire excellent strategic resources with the purpose of realising the ambitious development plan envisaged by the Company for the next five years. This operation confirms Sterling willingness to invest in the continuous evolution of a reality, that finds its roots in our genuine Umbria, with the intention of nurturing the development of the pharmaceutical sector in the local area and grow its position as a reference point at international level”, said Simone Ferlin, President and CEO of Sterling.   "FSI's investment, in support of Sterling and in partnership with the Ferlin family, aims to accelerate the development of a beautiful Umbrian company in the sector of production of active pharmaceutical ingredients, where Italy holds a leading position at the European and world level. The project, thanks to the capital increase made available to the company, aims to provide fuel for the company's growth by strengthening investment in R&D, expanding the production base, and ensuring financial flexibility for acquisitions. FSI has identified the pharmaceutical sector as a priority. The hope is to accompany the Ferlin family in a transformational growth process similar to the one we have been undertaking for years with the Marcucci family in Kedrion," said Maurizio Tamagnini, CEO of FSI.

"The objective is to participate with determination in a necessary evolution of a sector of great pride for our country. The new alliance with FSI is designed to equip Sterling with an important financial asset, which will enable it to acquire excellent strategic resources with the purpose of realising the ambitious development plan envisaged by the Company for the next five years. This operation confirms Sterling willingness to invest in the continuous evolution of a reality, that finds its roots in our genuine Umbria, with the intention of nurturing the development of the pharmaceutical sector in the local area and grow its position as a reference point at international level”, said Simone Ferlin, President and CEO of Sterling.   "FSI's investment, in support of Sterling and in partnership with the Ferlin family, aims to accelerate the development of a beautiful Umbrian company in the sector of production of active pharmaceutical ingredients, where Italy holds a leading position at the European and world level. The project, thanks to the capital increase made available to the company, aims to provide fuel for the company's growth by strengthening investment in R&D, expanding the production base, and ensuring financial flexibility for acquisitions. FSI has identified the pharmaceutical sector as a priority. The hope is to accompany the Ferlin family in a transformational growth process similar to the one we have been undertaking for years with the Marcucci family in Kedrion," said Maurizio Tamagnini, CEO of FSI.